BPC-157, TB-500 (Thymosin Beta-4), and GHK-Cu are research compounds. They are not approved for human administration. All information on this page is provided strictly for scientific and educational purposes. UNIK LAB does not provide medical advice.
Three compounds. Three distinct mechanisms. One research area that has quietly attracted more scientific attention than almost anything else in the connective tissue literature.
The combination of BPC-157, Thymosin Beta-4 (TB-500), and GHK-Cu — colloquially referred to in research circles as the "Wolverine Stack" — covers practically every known mechanism involved in connective tissue remodelling, angiogenesis, and cellular migration. What makes this triad genuinely interesting isn't any single compound; it's the mechanistic gaps each one fills that the others leave open.
1. What Is the Wolverine Stack?
The term "Wolverine Stack" emerged from the research community's habit of naming compound combinations after their studied outcomes. Each compound targets a distinct biological layer:
- BPC-157 (Body Protection Compound 157): a synthetic 15-amino acid peptide derived from a protective protein isolated from human gastric juice, studied primarily for musculoskeletal and connective tissue repair
- TB-500 / Thymosin Beta-4 (Tβ4): a 43-amino acid peptide naturally present in virtually all nucleated mammalian cells, studied for its role in actin sequestration, cellular migration, and wound healing
- GHK-Cu (Glycyl-Histidyl-Lysine with copper): a naturally occurring tripeptide found in human plasma, studied extensively for its role in tissue remodelling, collagen production, and regulation of hundreds of genes involved in tissue maintenance
The combination is not a licensed clinical protocol. All three are research compounds studied in preclinical settings (rodent models, cell culture) and early in vitro investigations.
2. BPC-157: Gastric Pentadecapeptide Background
BPC-157 was isolated from a protective protein in human gastric juice. It is stable in gastric acid at pH 1–2 (Sikiric group, 2004, PMID 15153646).
- Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV)
- Molecular weight: approximately 1,419 Da
- Stability: Stable in gastric acid at pH 1–2; unusual for a synthetic peptide
Research into BPC-157 has been conducted predominantly by the Zagreb University group led by Predrag Sikiric. Independent replication remains limited — researchers should bear this in mind when evaluating the data.
3. BPC-157 Mechanisms: Beyond Gastric Protection
Growth hormone receptor upregulation: Staresinic et al. (2014, PMID 25415472, Molecules) demonstrated that BPC-157 significantly upregulates growth hormone receptor (GHR) expression in tendon fibroblasts in vitro, providing direct mechanistic evidence for accelerated tendon repair in rodent models.
Nitric oxide pathway modulation: Several rodent studies have linked BPC-157 to nitric oxide synthase (NOS) pathway activity — NO is a key vasodilatory and angiogenic signalling molecule.
EGR-1 and VEGF upregulation: Expression of early growth response protein 1 (EGR-1) and vascular endothelial growth factor (VEGF) appears elevated in some preclinical models following BPC-157 administration.
For a direct compound-by-compound comparison, see our BPC-157 vs TB-500 comparative analysis.
4. Thymosin Beta-4 (TB-500): Actin Sequestration and Cellular Migration
Thymosin Beta-4 (Tβ4) has a research history dating back to the early 1980s. It is one of the most abundant peptides in virtually all nucleated mammalian cells.
- Sequence: 43 amino acids, with the LKKTET motif responsible for actin-binding activity
- Natural abundance: approximately 50–100 μmol/L in platelets
- Primary cellular role: G-actin sequestration — Tβ4 binds to monomeric (G) actin in a 1:1 ratio, preventing polymerisation into F-actin filaments. This regulated pool of unpolymerised actin is essential for controlled cellular migration.
5. TB-500 Mechanisms: Cardioprotection, Corneal Repair, Anti-inflammatory Activity
Corneal cytoprotection: Sosne et al. (2006, PMID 16630613) demonstrated that Tβ4 inhibits apoptosis in corneal epithelial cells exposed to benzalkonium chloride. The anti-apoptotic effect was mediated through inhibition of the NF-κB pathway.
NF-κB inhibition: The anti-inflammatory effects of Tβ4 appear partly mediated through inhibition of nuclear factor kappa B (NF-κB), a master regulator of inflammatory gene expression.
Where TB-500 differs from BPC-157: BPC-157 research focuses predominantly on mesenchymal tissue (tendons, ligaments, bone). TB-500/Tβ4 research covers a broader range of tissue types including cardiac, neural, and epithelial contexts.
6. GHK-Cu: The Tripeptide-Copper Complex
GHK-Cu was first identified in human plasma in 1973 by Loren Pickart. GHK appears in human plasma at approximately 200 ng/mL in young adults, declining to near-undetectable levels with age.
- Structure: Gly-His-Lys (three amino acids) chelated to a copper(II) ion
- Copper dependency: The copper(II) ion is functionally essential. Copper-free GHK shows significantly reduced bioactivity in most assays.
7. GHK-Cu Mechanisms: Collagen, Angiogenesis and Gene Regulation
Pickart et al. (2015, PMID 26236730) reported that GHK modulates at least 4,000 human genes — approximately 31% of all genes interrogated in a comprehensive microarray study.
Collagen synthesis: GHK-Cu promotes synthesis of both collagen I and collagen III, the primary structural collagens in skin, tendons, and ligaments (Pickart L, 2008, PMID 18644225).
Anti-fibrotic activity: Despite promoting collagen synthesis, GHK-Cu also appears to inhibit excessive fibrosis — downregulating TGF-β1-mediated fibrotic gene expression while maintaining normal wound-healing collagen synthesis.
8. Synergistic Mechanisms: Why Three Pathways Matter
- Layer 1 — Structural repair and vascularisation: BPC-157 addresses tendon-to-bone junction repair, growth hormone receptor amplification, and VEGF-mediated angiogenesis.
- Layer 2 — Cellular migration: TB-500's actin sequestration activity enables directed cellular migration — the process by which repair cells physically move toward the injury site.
- Layer 3 — Extracellular matrix quality: GHK-Cu provides the collagen quality control layer — ensuring that synthesised collagen is properly organised, fibrosis is restrained, and antioxidant defences are upregulated.
9. Comparative Overview: Wolverine Stack vs. Individual Compounds
| Parameter | BPC-157 | TB-500 (Tβ4) | GHK-Cu | Combination |
|---|---|---|---|---|
| Primary mechanism | GH receptor / NO / VEGF upregulation | Actin sequestration / cellular migration | Gene regulation / collagen / SOD | All three pathways concurrently |
| Target tissue | Tendon, ligament, GI, bone | Cardiac, corneal, muscle, neural | Skin, collagen matrix, wound | Broad connective tissue coverage |
| Anti-inflammatory | Yes (cytokine reduction, preclinical) | Yes (NF-κB inhibition) | Yes (antioxidant enzyme upregulation) | Multi-pathway anti-inflammatory |
| Angiogenesis | VEGF, EGR-1 (preclinical) | Indirect (via cell migration) | VEGF upregulation (fibroblast) | Dual VEGF + structural support |
| Human clinical data | None (preclinical only) | Limited (Phase I ophthalmic) | Some (topical wound healing) | None (combination not trialled) |
| Stability (aqueous) | Stable (pH 1–7) | Moderate (protect from oxidation) | Stable when copper-bound | Prepare separately; compatible |
| Research status | Research compound — not approved | Research compound — not approved | Research compound — not approved | Not approved, not trialled in combination |
10. Reconstitution and Stability Considerations
These notes apply strictly to in vitro and laboratory research contexts. They are not instructions for human administration.
- BPC-157: Reconstitute with bacteriostatic water. Stable at 4°C for ~3–5 days in solution; maintain as lyophilised powder at −20°C for longer storage.
- TB-500 (Thymosin Beta-4): Reconstitute with bacteriostatic water. Sensitive to oxidation; longer chain (43 aa) makes it more susceptible to degradation than BPC-157.
- GHK-Cu: Copper chelation is critical; copper-free GHK shows significantly reduced bioactivity. Stable at room temperature when properly sealed; light-sensitive.
- Compatibility: No published studies have investigated chemical compatibility of these three compounds when combined in solution. Each should be prepared and stored separately.
11. Research Findings Summary Table
| Study / PMID | Compound | Model | Key Finding | Limitation |
|---|---|---|---|---|
| Lovric-Bencic 2004 (PMID 15153646) | BPC-157 | Rat/mouse (cardiac) | Reversed doxorubicin-induced cardiac failure; restored endothelin-1 levels | Animal model; no human data |
| Škrlec 2018 (PMID 30191288) | BPC-157 | In vitro / bacterial | BPC-157 stable through bacterial expression; antioxidant activity confirmed | Delivery system study; not therapeutic endpoint |
| Sosne 2006 (PMID 16630613) | TB-500 (Tβ4) | Cell culture (corneal) | Tβ4 inhibited BAK-mediated apoptosis via NF-κB pathway | In vitro; limited translational data |
| Pickart 2015 (PMID 26236730) | GHK-Cu | Microarray / cell culture | GHK regulates ~4,000 human genes; broad effects on repair, inflammation, antioxidant pathways | Gene expression data; functional outcomes vary |
| Pickart 2008 (PMID 18644225) | GHK-Cu | Review / cell culture | GHK promotes collagen I/III, fibronectin, anti-fibrotic TGF-β1 modulation | Much data from Pickart's own laboratory |
| Staresinic 2014 (PMID 25415472) | BPC-157 | Cell culture (tendon) | BPC-157 upregulates growth hormone receptor in tendon fibroblasts | In vitro; primary mechanism for tendon repair |
12. FAQ: Frequently Asked Questions
What is the scientific rationale for the Wolverine Stack?
The combination of BPC-157, TB-500 (Thymosin Beta-4), and GHK-Cu is studied because the three compounds cover mechanistically distinct aspects of connective tissue repair: BPC-157 for structural repair pathways and angiogenesis, TB-500 for actin-driven cellular migration, and GHK-Cu for collagen quality and broad gene regulation (~4,000 genes). No single compound covers all three layers.
Is BPC-157 approved for human use?
No. BPC-157 is a research compound without approval from any regulatory authority (FDA, EMA, Health Canada). All published data derives from preclinical models.
What is the difference between TB-500 and Thymosin Beta-4?
TB-500 is a trade name for synthetic Thymosin Beta-4 (Tβ4). The active compounds are identical. For research citation purposes, researchers should cite Tβ4 studies directly.
Does GHK-Cu work without the copper component?
Research data consistently shows that copper-free GHK has significantly reduced bioactivity. The copper(II) ion appears essential for receptor binding and gene regulatory activity. Researchers should confirm the copper content and chelation status of their material.
What does 'not for human administration' mean for research chemicals?
Research chemicals have not completed the clinical trial process required for regulatory approval. They may be used in laboratory settings under appropriate ethics oversight. They should not be self-administered or administered outside an approved research context.
How does the Wolverine Stack compare to anabolic steroids for connective tissue research?
Anabolic steroids primarily drive protein synthesis via androgen receptor activation. The Wolverine Stack compounds act via different mechanisms: NO/VEGF signalling (BPC-157), actin sequestration/NF-κB (TB-500), and multi-gene regulation covering ~4,000 genes (GHK-Cu). These pathways are orthogonal to the anabolic steroid pathway — relevant to research designs comparing these compound classes.

Referenced Studies
- Lovric-Bencic M, Sikiric P et al. “Doxorubicine-congestive heart failure-increased big endothelin-1 plasma concentration: reversal by BPC 157.” J Pharmacol Sci. 2004. PMID 15153646
- Škrlec K, Ručman R, Sikiric P et al. “Engineering recombinant Lactococcus lactis as a delivery vehicle for BPC-157 peptide with antioxidant activities.” Appl Microbiol Biotechnol. 2018. PMID 30191288
- Sosne G et al. “Thymosin beta4 inhibits benzalkonium chloride-mediated apoptosis in corneal and conjunctival epithelial cells.” Exp Eye Res. 2006. PMID 16630613
- Pickart L, Vasquez-Soltero JM, Margolina A. “GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.” Biomed Res Int. 2015. PMID 26236730
- Pickart L. “The human tri-peptide GHK and tissue remodeling.” J Biomater Sci Polym Ed. 2008. PMID 18644225
- Staresinic M et al. “Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts.” Molecules. 2014. PMID 25415472
Available from UNIK LAB
Research Peptides
Research-grade Research Peptides · HPLC verified ≥98% · COA included · 48h EU/UK dispatch
